Inborn Errors of Metabolism (IEMs): Advances in Diagnosis and Treatment

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Genetic Diagnosis".

Deadline for manuscript submissions: 25 July 2025 | Viewed by 132

Special Issue Editor


E-Mail Website
Guest Editor
Department of Genetics, Children’s Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA
Interests: genetic; inborn disease; arginase deficiency; Phenylketonuria; fatty acid oxidation disorders; lysosomal disorders

Special Issue Information

Dear Colleagues,

Newborn screening for Inborn Errors of Metabolism (IEMs) is one the most important public health initiatives of this century. It was initially introduced in the 1960s as a part of the population screening for malignancies conducted by Dr. Robert Guthrie, who had previously realized that blood from a newborn baby's heel onto filter paper could be eluted and tested for phenylketonuria. Subsequently, other amino acid disorders, organic acidurias, and some urea cycle disorders could similarly be tested.

For several years, a single disorder was diagnosed through a single test. In the 1960s, fatty acid oxidation disorders, especially medium-chain acylcarnitine deficiency (MCAD), had significant mortality in the newborn period. In order to test as many infants as possible, tandem mass spectrometry (MS-MS) was performed, which could identify pathogenic acylcarnitines very quickly, confirm the diagnosis, and start treatment. Pilot studies were carried out in Australia, Germany, and the US, with much success. However, in the US, each state determines how to manage the NBS programs, often with limited testing panels. Now, however, each US state tests the whole panel, and most countries have standard testing.

Meanwhile, more disorders are being added to the panels, e.g., lysosomal disorders, lipidoses, cystic fibrosis, and galactosemia.

Currently, there is much discussion on whether it would be more beneficial to move to whole exome sequencing. The UK soon plans for every newborn to have whole exome sequencing (WES). However, there is concern about cost and the interpretation of the results.

In light of these ongoing discussions, this Special Issue welcomes submissions of original research articles, review papers, and opinion pieces to share the latest findings, experiences, and perspectives on newborn screening and clinical management for inborn errors of metabolism (IEMs).

Dr. Deborah Marsden
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • filter papers
  • tandem MS-MS
  • whole exome sequencing
  • phenylketonuria
  • fatty acid oxidation disorders
  • newborn screening
  • inborn errors of metabolism (IEMs)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 2266 KiB  
Review
Single Amino Acid Supplementation in Inherited Metabolic Disorders: An Evidence-Based Review of Interventions
by Elvira Verduci, Martina Tosi, Carlo Dionisi Vici and Marco Spada
Genes 2025, 16(5), 502; https://doi.org/10.3390/genes16050502 (registering DOI) - 27 Apr 2025
Viewed by 47
Abstract
Background/Objectives: Inherited metabolic disorders (IMDs) are a group of genetic conditions affecting metabolic pathways. The treatment of some IMDs requires the dietary restriction of specific amino acids. IMDs may also necessitate the supplementation of one or more amino acids due to factors such [...] Read more.
Background/Objectives: Inherited metabolic disorders (IMDs) are a group of genetic conditions affecting metabolic pathways. The treatment of some IMDs requires the dietary restriction of specific amino acids. IMDs may also necessitate the supplementation of one or more amino acids due to factors such as reduced dietary intake, impaired synthesis, defective transport or absorption, or increased utilization. This literature review aims to evaluate the most recent evidence regarding amino acid supplementation in IMDs, considering not only the prevention of amino acid deficiency and toxic accumulation but also the competition with other toxic metabolites. Methods: A systematic search strategy was developed and applied to PubMed/Medline and Scopus databases to identify relevant studies. Amino acids were categorized into six groups: branched-chain amino acids, aromatic amino acids, sulfur amino acids, urea cycle amino acids, other essential amino acids, and other non-essential amino acids. Results: A total of 24 rare IMDs were evaluated. A final number of 99 selected articles were assessed based on the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence. Although this work represents a preliminary non-systematic review, it highlights the need for further studies and data collection. Conclusions: Future research must establish the plasma amino acid levels that indicate the need for supplementation, specify the appropriate dosages (g/day or mg/kg/day), determine the optimal treatment duration, and, crucially, define the target plasma ranges to be maintained for effective management of IMDs. Full article
Show Figures

Figure 1

Back to TopTop